Absci (NASDAQ:ABSI) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Absci (NASDAQ:ABSI) in a research note issued to investors on Wednesday morning,Benzinga reports. The brokerage currently has a $7.00 target price on the stock. HC Wainwright also issued estimates for Absci’s Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.83) EPS, FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.31) EPS, FY2028 earnings at $0.20 EPS and FY2029 earnings at ($0.02) EPS.

Several other research firms have also recently weighed in on ABSI. Needham & Company LLC reissued a “buy” rating and issued a $9.00 price objective on shares of Absci in a research report on Wednesday. Guggenheim reissued a “buy” rating and issued a $10.00 price objective on shares of Absci in a research report on Tuesday, December 3rd. Finally, KeyCorp reduced their price objective on Absci from $6.00 to $5.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $8.57.

Absci Stock Down 1.0 %

Shares of Absci stock opened at $3.01 on Wednesday. The stock has a market capitalization of $383.28 million, a P/E ratio of -3.24 and a beta of 2.09. The company has a quick ratio of 5.63, a current ratio of 5.63 and a debt-to-equity ratio of 0.01. The stock has a 50 day moving average price of $3.86 and a two-hundred day moving average price of $3.66. Absci has a 12-month low of $2.45 and a 12-month high of $6.72.

Absci (NASDAQ:ABSI) last announced its earnings results on Tuesday, March 18th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.03). The company had revenue of $0.67 million for the quarter, compared to the consensus estimate of $1.77 million. Absci had a negative return on equity of 46.56% and a negative net margin of 2,321.56%. Equities analysts expect that Absci will post -0.89 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. PCA Investment Advisory Services Inc. acquired a new position in Absci during the fourth quarter worth $26,000. Alpha Cubed Investments LLC acquired a new stake in shares of Absci in the fourth quarter valued at $26,000. Ballentine Partners LLC acquired a new stake in shares of Absci in the fourth quarter valued at $27,000. BNP Paribas Financial Markets acquired a new stake in shares of Absci in the fourth quarter valued at $28,000. Finally, Verdence Capital Advisors LLC bought a new position in Absci in the fourth quarter valued at about $37,000. 52.05% of the stock is owned by institutional investors.

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.